Cardiac Wire #230 December 2, 2024
Winrevair Wins Again | Boards Are Big Business
Cardiac Wire #229 November 25, 2024
Muvalaplin Aces Lp(a) Test | A New ATTR-CM Option
Cardiac Wire #228 November 21, 2024
AHA 2024 Highlights | First-Line VT Ablation
Cardiac Wire #227 November 18, 2024
Tirzepatide’s Prediabetes Triumph | Valvosoft Hits Endpoints
Cardiac Wire #226 November 14, 2024
The SAFEty of IVC Filters | CKM & CVD
Cardiac Wire #225 November 11, 2024
LimFlow Limits CLTI | J&J’s PFA Play
Cardiac Wire #224 November 7, 2024
Boston Scientific Bolsters AFib Mapping | Hypertension’s Digital Problem
Cardiac Wire #223 November 4, 2024
TCT 2024’s Top TAVR Studies | CCTA’s Big Day
Cardiac Wire #222 October 31, 2024
The Best in Cardiology | Reconsidering Colchicine
Cardiac Wire #221 October 28, 2024
America’s CVD Problem | BAC & CAC Screening
Cardiac Wire #220 October 24, 2024
The State of Cardiology | Oral GLP-1’s CV Potential
Cardiac Wire #219 October 21, 2024
Questioning Semaglutide’s CVD Impact | iCardio Clearance
Cardiac Wire #218 October 17, 2024
AFib Inhaler’s Mixed Results | Spironolactone Spirals
Cardiac Wire #217 October 10, 2024
AstraZeneca’s New Lp(a) Candidate | Aortic Stenosis AI Breakthrough
Cardiac Wire #216 October 7, 2024
Finerenone’s Early HF Impact | Rivus’ Obesity HFpEF Potential
Cardiac Wire #215 October 3, 2024
Mavacamten’s HFpEF Potential | Swiss Army Surgery
Cardiac Wire #214 September 30, 2024
Preventing Post-Cancer CVD | J&J’s Cardiometabolic Shutdown
Cardiac Wire #213 September 26, 2024
Istaroximes’ Cardiogenic Shock Impact | RPM Scrutiny
Cardiac Wire #212 September 23, 2024
